Skip to main content
Top
Published in: Acta Diabetologica 3/2009

01-09-2009 | Original Article

Glucose homeostasis abnormalities in cardiac intensive care unit patients

Authors: Jacob Ilany, Ibrahim Marai, Ohad Cohen, Shlomi Matetzky, Malka Gorfine, Idit Erez, Hanoch Hod, Avraham Karasik

Published in: Acta Diabetologica | Issue 3/2009

Login to get access

Abstract

The aim of this study was to characterize the abnormalities in glucose homeostasis in intensive care unit patients following an acute coronary event. The study population included all non-diabetic patients ages 20–80 years that were admitted to a coronary intensive unit. Glucose, insulin and C-peptide levels during an oral glucose tolerance test (OGTT) were measured during the acute admission. From January to September 2003, 277 patients were admitted to the coronary unit. Of these, 127 patients underwent an OGTT. Of these, only 29 patients (23%) exhibited normal glucose metabolism. The remainder had type 2 diabetes (32%), impaired glucose tolerance (37%) or isolated impaired fasting glucose (8%, 100–125 mg/dl). Based on homeostasis model assessment (HOMA) calculations, diabetic patients had impaired β-cell function and patients with elevated fasting glucose levels were insulin resistant. Beta-cell dysfunction during the acute stress seems to contribute to the glucose abnormalities. Most patients who experience an acute coronary event demonstrate abnormal glucose metabolism. Post glucose-load abnormalities are more common than abnormal fasting glucose level in this situation. It is postulated that the acute stress of a coronary event may contribute to the dysglycemia.
Literature
1.
go back to reference Gerstein HC (1998) Dysglycaemia: a cardiovascular risk factor. Diabetes Res Clin Pract 40(suppl):S9–S14PubMedCrossRef Gerstein HC (1998) Dysglycaemia: a cardiovascular risk factor. Diabetes Res Clin Pract 40(suppl):S9–S14PubMedCrossRef
2.
go back to reference Haffner SM (1998) The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 19:583–592PubMedCrossRef Haffner SM (1998) The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 19:583–592PubMedCrossRef
3.
go back to reference Tai ES, Goh SY, Lee JJM, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, Chia KS, Tan CE (2004) Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 27:1728–1734PubMedCrossRef Tai ES, Goh SY, Lee JJM, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, Chia KS, Tan CE (2004) Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 27:1728–1734PubMedCrossRef
4.
go back to reference Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata diabetes study. Diabetes Care 22:920–924PubMedCrossRef Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata diabetes study. Diabetes Care 22:920–924PubMedCrossRef
5.
go back to reference Choi KM, Lee KW, Kim SG, Kim NH, Park CG, Seo HS, Oh DJ, Choi DS, Baik SH (2005) Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab 90:175–180PubMedCrossRef Choi KM, Lee KW, Kim SG, Kim NH, Park CG, Seo HS, Oh DJ, Choi DS, Baik SH (2005) Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab 90:175–180PubMedCrossRef
6.
go back to reference Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144PubMedCrossRef Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144PubMedCrossRef
7.
go back to reference Ramachandran A, Chamukuttan S, Immaneni S, Shanmugam RM, Vishnu N, Viswanathan V, Jaakko T (2005) High incidence of glucose intolerance in Asian-Indian subjects with acute coronary syndrome. Diabetes Care 28:2492–2496PubMedCrossRef Ramachandran A, Chamukuttan S, Immaneni S, Shanmugam RM, Vishnu N, Viswanathan V, Jaakko T (2005) High incidence of glucose intolerance in Asian-Indian subjects with acute coronary syndrome. Diabetes Care 28:2492–2496PubMedCrossRef
8.
go back to reference Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L (1999) Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes 23:512–517CrossRef Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L (1999) Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes 23:512–517CrossRef
9.
go back to reference Unwin N, Shaw J, Zimmet P, Alberti KGMM (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708–723PubMedCrossRef Unwin N, Shaw J, Zimmet P, Alberti KGMM (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708–723PubMedCrossRef
10.
go back to reference The expert committee on the diagnosis, classification of diabetes mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRef The expert committee on the diagnosis, classification of diabetes mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRef
11.
go back to reference Kuhl J, Hilding A, Östenson CG, Grill V, Efendic S, Båvenholm P (2005) Characterisation of subjects with early abnormalities of glucose tolerance in the stockholm diabetes prevention programme: the impact of sex and type 2 diabetes heredity. Diabetologia 48:35–40PubMedCrossRef Kuhl J, Hilding A, Östenson CG, Grill V, Efendic S, Båvenholm P (2005) Characterisation of subjects with early abnormalities of glucose tolerance in the stockholm diabetes prevention programme: the impact of sex and type 2 diabetes heredity. Diabetologia 48:35–40PubMedCrossRef
12.
go back to reference Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study. Diabetes 55:1430–1435PubMedCrossRef Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study. Diabetes 55:1430–1435PubMedCrossRef
13.
go back to reference Festa A, D’Agostino R Jr, Hanley AJG, Karter AJ, Saad MF, Haffner SM (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53:1549–1555PubMedCrossRef Festa A, D’Agostino R Jr, Hanley AJG, Karter AJ, Saad MF, Haffner SM (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53:1549–1555PubMedCrossRef
14.
go back to reference Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T (2003) Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care 26:868–874PubMedCrossRef Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T (2003) Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care 26:868–874PubMedCrossRef
15.
go back to reference Hsieh CH, Kuo SW, Hung YJ, Shen DC, Ho CT, Lian WC, Lee CH, Fan SC, Pei D (2005) Metabolic characteristics in individuals with impaired glucose homeostasis. Int J Clin Pract 59:639–644PubMedCrossRef Hsieh CH, Kuo SW, Hung YJ, Shen DC, Ho CT, Lian WC, Lee CH, Fan SC, Pei D (2005) Metabolic characteristics in individuals with impaired glucose homeostasis. Int J Clin Pract 59:639–644PubMedCrossRef
16.
go back to reference The DECODE Study Group (2003) Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26:61–69CrossRef The DECODE Study Group (2003) Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26:61–69CrossRef
17.
go back to reference Hanley AJG, Williams K, Stern MP, Haffner SM (2002) Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the san antonio heart study. Diabetes Care 25:1177–1184PubMedCrossRef Hanley AJG, Williams K, Stern MP, Haffner SM (2002) Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the san antonio heart study. Diabetes Care 25:1177–1184PubMedCrossRef
18.
go back to reference Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139PubMedCrossRef Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139PubMedCrossRef
19.
go back to reference Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885PubMedCrossRef Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885PubMedCrossRef
20.
go back to reference Welin L, Bresäter LE, Eriksson H, Hansson PO, Welin C, Rosengren A (2003) Insulin resistance and other risk factors for coronary heart disease in elderly men: the study of men born in 1913 and 1923. Eur J Cardiovasc Prevention Rehab 10:283–288CrossRef Welin L, Bresäter LE, Eriksson H, Hansson PO, Welin C, Rosengren A (2003) Insulin resistance and other risk factors for coronary heart disease in elderly men: the study of men born in 1913 and 1923. Eur J Cardiovasc Prevention Rehab 10:283–288CrossRef
21.
go back to reference Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P (2004) Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes Care 27:781–787PubMedCrossRef Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P (2004) Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes Care 27:781–787PubMedCrossRef
22.
go back to reference Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957PubMedCrossRef Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957PubMedCrossRef
23.
go back to reference Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M (2006) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga diabetes study. J Clin Endocrinol Metab 91:813–819PubMedCrossRef Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M (2006) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga diabetes study. J Clin Endocrinol Metab 91:813–819PubMedCrossRef
24.
go back to reference Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494PubMedCrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494PubMedCrossRef
25.
go back to reference Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10–16PubMedCrossRef Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10–16PubMedCrossRef
26.
go back to reference UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
27.
go back to reference Bock G, Man CD, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R (2006) Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55:3536–3549PubMedCrossRef Bock G, Man CD, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R (2006) Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55:3536–3549PubMedCrossRef
28.
go back to reference Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE (2002) Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129–1134PubMedCrossRef Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE (2002) Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129–1134PubMedCrossRef
29.
go back to reference Tenerz Å, Norhammar A, Silveira A, Hamsten A, Nilsson G, Rydén L, Malmberg K (2003) Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 26:2770–2776PubMedCrossRef Tenerz Å, Norhammar A, Silveira A, Hamsten A, Nilsson G, Rydén L, Malmberg K (2003) Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 26:2770–2776PubMedCrossRef
30.
go back to reference Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Öhrvik J (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: the Euro heart survey on diabetes and the heart. Eur Heart J 25:1880–1890PubMedCrossRef Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Öhrvik J (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: the Euro heart survey on diabetes and the heart. Eur Heart J 25:1880–1890PubMedCrossRef
31.
go back to reference Rathmann W, Icks A, Haastert B, Giani G, Lowel H, Mielck A (2002) Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol 91:620–625PubMedCrossRef Rathmann W, Icks A, Haastert B, Giani G, Lowel H, Mielck A (2002) Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol 91:620–625PubMedCrossRef
32.
go back to reference Shiloah E, Witz S, Abramovitch Y, Cohen O, Buchs A, Ramot Y, Weiss M, Unger A, Rapoport MJ (2003) Effect of acute psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes Care 26:1462–1467PubMedCrossRef Shiloah E, Witz S, Abramovitch Y, Cohen O, Buchs A, Ramot Y, Weiss M, Unger A, Rapoport MJ (2003) Effect of acute psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes Care 26:1462–1467PubMedCrossRef
33.
go back to reference Wallander M, Bartnik M, Efendic S, Hamsten A, Malmberg K, Ohrvik J, Ryden L, Silveira A, Norhammar A (2005) Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 48:2229–2235PubMedCrossRef Wallander M, Bartnik M, Efendic S, Hamsten A, Malmberg K, Ohrvik J, Ryden L, Silveira A, Norhammar A (2005) Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 48:2229–2235PubMedCrossRef
Metadata
Title
Glucose homeostasis abnormalities in cardiac intensive care unit patients
Authors
Jacob Ilany
Ibrahim Marai
Ohad Cohen
Shlomi Matetzky
Malka Gorfine
Idit Erez
Hanoch Hod
Avraham Karasik
Publication date
01-09-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-008-0077-0

Other articles of this Issue 3/2009

Acta Diabetologica 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine